CNW/ - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health ...

Health Canada has approved a second drug that targets the underlying cause of Alzheimer’s disease, a development that could ...

Health Canada approved Lilly’s $47,250 Alzheimer’s drug Kisunla, raising new questions over public reimbursement.

At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...

Health Canada has approved a new once-monthly drug for people living with early symptomatic Alzheimer’s disease. Donanemab is ...

Alzheimer’s Research UK says patients at risk of being left behind as lack of formal or accurate diagnoses closes door to trials ...

Health Canada has approved Eli Lilly’s donanemab, sold as Kisunla, as the country’s second disease-modifying Alzheimer’s ...

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

Alzheimer's Disease," Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell continue their ...

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.